San Antonio Breast Cancer Symposium

Abstract submission is open for the San Antonio Breast Cancer Symposium, December 8-11, 2026. Abstract deadline: July 13. Learn more:
https://brnw.ch/21x3sCi

Breast cancer clinicians and scientists from around the world will come together at (December 8-11). Submit an abstract by July 13 and join them. Learn more:
https://brnw.ch/21x3daj

The abstract deadline for is July 13. Submit an abstract today and join us December 8-11 for the most important breast cancer meeting in the world. Learn more:
https://brnw.ch/21x35Wz

SABCS co-directors Virginia Kaklamani, MD, and Carlos Arteaga, MD, and program director Kate Lathrop, MD, joined colleagues from around the world at last week.

What discoveries will define the next chapter of breast cancer research?

Join us at in December to find out.

Housing is now open for (December 8-11). Make your reservations now to secure the best available hotels. Deadline: November 30. Learn more: https://bit.ly/3PDuT0e

Three recent FDA approvals for breast cancer treatments are drawing national and local attention.

KENS 5 spoke with Dr. Kate Lathrop, SABCS program director and breast medical oncologist at UT Health San Antonio's Mays Cancer Center, about the importance of these scientific advances for patients. Clinical trial results related to the approvals were presented at SABCS.

FDA approves new breast cancer treatments, offering hope for early and late-stage patients Three FDA breakthrough approvals for breast cancer treatments presented at the San Antonio Breast Cancer Symposium are offering new hope for patients battling both early and late-stage breast cancer. ...

Submit an abstract by July 13 and share your work with the global breast cancer research community at (December 8-11). Learn more:
https://brnw.ch/21x2Skg

Today, the FDA approved the targeted therapy datopotamab deruxtecan-dlnk for adult patients with unresectable or metastatic TNBC who are not candidates for certain immune checkpoint inhibitors. The approval was based on data from the TROPION-Breast02 study, which was presented at , and Sara Tolaney discussed how this treatment might impact the therapeutic landscape for metastatic TNBC in an Educational Session at the Symposium. Learn more:
https://brnw.ch/21x2K1Y

Breast cancer clinicians and scientists from around the world will come together at (December 8-11). Submit an abstract by July 13 and join them. Learn more:
https://brnw.ch/21x2HDY